<DOC>
	<DOC>NCT00035867</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of TLK199 in patients with myelodysplastic syndrome (MDS).</brief_summary>
	<brief_title>Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Histologically or cytologically confirmed diagnosis of MDS Adequate liver and kidney function Ineligible for, or refusing, allogeneic bone marrow transplant At least 18 years of age Discontinuation of growth factors (e.g., G CSF) at least 2 weeks prior to study entry Failure to recover from any prior surgery, or any major surgery within 4 weeks of study entry Pregnant or lactating women History of allergy to eggs Other investigational drugs within 14 days of study entry Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry Concomitant steroids or hormones for the treatment of neoplasms</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
</DOC>